OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Recent advances in immunotherapy for hepatocellular carcinoma
Abid Khan, Zhikun Liu, Xiao Xu
Hepatobiliary & pancreatic diseases international (2021) Vol. 20, Iss. 6, pp. 511-520
Closed Access | Times Cited: 47
Abid Khan, Zhikun Liu, Xiao Xu
Hepatobiliary & pancreatic diseases international (2021) Vol. 20, Iss. 6, pp. 511-520
Closed Access | Times Cited: 47
Showing 1-25 of 47 citing articles:
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 119
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 119
Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma
Qiangnu Zhang, Lingfeng Xiong, Wei Teng, et al.
Oncogene (2023) Vol. 42, Iss. 19, pp. 1509-1523
Closed Access | Times Cited: 54
Qiangnu Zhang, Lingfeng Xiong, Wei Teng, et al.
Oncogene (2023) Vol. 42, Iss. 19, pp. 1509-1523
Closed Access | Times Cited: 54
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Yinjie Fan, Hang Xue, Hua‐chuan Zheng
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 233-263
Open Access | Times Cited: 46
Yinjie Fan, Hang Xue, Hua‐chuan Zheng
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 233-263
Open Access | Times Cited: 46
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
Jiong-Jie Yu, Sunbin Ling, Jiachen Hong, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007479-e007479
Open Access | Times Cited: 23
Jiong-Jie Yu, Sunbin Ling, Jiachen Hong, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007479-e007479
Open Access | Times Cited: 23
Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights
Sanchita Rauth, Mokenge P. Malafa, Moorthy P. Ponnusamy, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 867-884
Closed Access | Times Cited: 13
Sanchita Rauth, Mokenge P. Malafa, Moorthy P. Ponnusamy, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 867-884
Closed Access | Times Cited: 13
Harnessing Immunotherapy for Hepatocellular Carcinoma: Principles and Emerging Promises
Hossein Miri, Payman Rahimzadeh, Mehrdad Hashemi, et al.
Pathology - Research and Practice (2025), pp. 155928-155928
Closed Access | Times Cited: 1
Hossein Miri, Payman Rahimzadeh, Mehrdad Hashemi, et al.
Pathology - Research and Practice (2025), pp. 155928-155928
Closed Access | Times Cited: 1
m 6 A-modification regulated circ-CCT3 acts as the sponge of miR-378a-3p to promote hepatocellular carcinoma progression
Hua Liu, Yifan Jiang, Jiahua Lu, et al.
Epigenetics (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 19
Hua Liu, Yifan Jiang, Jiahua Lu, et al.
Epigenetics (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 19
Silibinin, a potential fasting mimetic, inhibits hepatocellular carcinoma by triggering extrinsic apoptosis
Biying Xiao, Yanyu Jiang, Shuying Yuan, et al.
MedComm (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 7
Biying Xiao, Yanyu Jiang, Shuying Yuan, et al.
MedComm (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 7
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Advances in multi-omics research on viral hepatitis
Ze Xiang, Jiayuan Li, Di Lu, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 25
Ze Xiang, Jiayuan Li, Di Lu, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 25
Biomarkers for response to immunotherapy in hepatobiliary malignancies
Zhifei Lin, Lun‐Xiu Qin, Jinhong Chen
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 413-419
Closed Access | Times Cited: 23
Zhifei Lin, Lun‐Xiu Qin, Jinhong Chen
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 413-419
Closed Access | Times Cited: 23
IDI1 inhibits the cGAS-Sting signaling pathway in hepatocellular carcinoma
Lin Fu, Hui Ding, Yangqiu Bai, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27205-e27205
Open Access | Times Cited: 4
Lin Fu, Hui Ding, Yangqiu Bai, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27205-e27205
Open Access | Times Cited: 4
Pei Guo, Liyuan Zhong, Tao Wang, et al.
Scandinavian Journal of Immunology (2025) Vol. 101, Iss. 2
Closed Access
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer
Shaukat Ali, Mahnoor Arshad, Muhammad Summer, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Shaukat Ali, Mahnoor Arshad, Muhammad Summer, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Model for end-stage liver disease-dependent prognostic capacity of platelet-to-lymphocyte ratio following liver transplantation for hepatocellular carcinoma
Chiyu He, Weiliang Shen, Zuyuan Lin, et al.
Transplant Immunology (2024) Vol. 85, pp. 102071-102071
Closed Access | Times Cited: 3
Chiyu He, Weiliang Shen, Zuyuan Lin, et al.
Transplant Immunology (2024) Vol. 85, pp. 102071-102071
Closed Access | Times Cited: 3
B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1
Jiatao Li, Juan Feng, Ziyong Li, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Jiatao Li, Juan Feng, Ziyong Li, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Artemiprincepsolides A—F, Novel Germacrane‐guaiane and Eudesmane‐guaiane Sesquiterpenoid Dimers from Artemisia princeps and Their Antihepatoma Activity
Li‐Hua Su, Wenjing Ma, Yun‐Bao Ma, et al.
Chinese Journal of Chemistry (2023) Vol. 41, Iss. 20, pp. 2648-2656
Closed Access | Times Cited: 9
Li‐Hua Su, Wenjing Ma, Yun‐Bao Ma, et al.
Chinese Journal of Chemistry (2023) Vol. 41, Iss. 20, pp. 2648-2656
Closed Access | Times Cited: 9
Development and Validation of a Novel Nomogram Integrated with Hypoxic and Lactate Metabolic Characteristics for Prognosis Prediction in Hepatocellular Carcinoma
Xun Qiu, Libin Dong, Kai Wang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 241-255
Open Access | Times Cited: 3
Xun Qiu, Libin Dong, Kai Wang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 241-255
Open Access | Times Cited: 3
Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression
Nan Xu, Jianyong Zhuo, Yiyuan Chen, et al.
British Journal of Cancer (2023) Vol. 130, Iss. 2, pp. 201-212
Closed Access | Times Cited: 7
Nan Xu, Jianyong Zhuo, Yiyuan Chen, et al.
British Journal of Cancer (2023) Vol. 130, Iss. 2, pp. 201-212
Closed Access | Times Cited: 7
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
Diego J Jiménez, Aadil Javed, Teresa Rubio‐Tomás, et al.
(2024)
Open Access | Times Cited: 2
Diego J Jiménez, Aadil Javed, Teresa Rubio‐Tomás, et al.
(2024)
Open Access | Times Cited: 2
Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR ‐224/HOXD10 axis
Wenting Wang, Tao Wang, Hongyun Lin, et al.
Environmental Toxicology (2024) Vol. 39, Iss. 4, pp. 2429-2438
Closed Access | Times Cited: 2
Wenting Wang, Tao Wang, Hongyun Lin, et al.
Environmental Toxicology (2024) Vol. 39, Iss. 4, pp. 2429-2438
Closed Access | Times Cited: 2
Current and emerging immunotherapeutic approaches for biliary tract cancers
Zhengang Yuan, Tianmei Zeng, Chen‐jie Tao
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 440-449
Closed Access | Times Cited: 11
Zhengang Yuan, Tianmei Zeng, Chen‐jie Tao
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 440-449
Closed Access | Times Cited: 11
Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes
Chen Xue, Xinyu Gu, Yalei Zhao, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Chen Xue, Xinyu Gu, Yalei Zhao, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Application of Immunotherapy in Hepatocellular Carcinoma
Lele Miao, Zhengchao Zhang, Zhijian Ren, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 14
Lele Miao, Zhengchao Zhang, Zhijian Ren, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 14
Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models
Kyungmi Yang, Changhoon Choi, H. Cho, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1811-1811
Open Access | Times Cited: 12
Kyungmi Yang, Changhoon Choi, H. Cho, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1811-1811
Open Access | Times Cited: 12
